
    
      Patient population will include preterm infants born at 24 - 36+6 weeks of gestation who are
      candidates for non-invasive respiratory support post extubation or as primary respiratory
      support after birth. They will be will be randomized to 2 groups: Heated Humidified High Flow
      Nasal Cannula (HHHFNC) and Nasal Intermittent Positive Pressure Ventilation (NIPPV).

      This will be a prospective unblinded randomized controlled study, designed as a
      non-inferiority trial.

      Primary outcome: The primary outcome will be rate of treatment failure (need for intubation)
      within 7 days of starting the study treatment
    
  